NYSE:ORN - Post Discussion
Post by
whytestocks on Oct 01, 2024 2:45pm
ORYZON receives minutes from End-of-Phase II meeting with th
Just In: $ORN ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality DisorderFDA’s feedback supports the initiation of the Phase III trial Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 Currently ...
ORN - ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
Be the first to comment on this post